BIO urges Florida Governor Scott to sign House Bill 365 – a bill related to the substitution of biologic and biosimilar medicines – which recently passed out of the Legislature.
BIO supports passage of Florida House Bill 365, which provides requirements for pharmacist to dispense substitute biological products that are determined to be interchangeable for prescribed biological product.
To ensure transparency and communication between patients and their treatment teams, BIO believes that certain safeguards should guide substitution policies for interchangeable biologics under state law as well.
The policies outlined in Senate Bill 2190 align with all five of BIO’s Principles on Biologic Product Substitution and we therefore support its passage.
Oregon Governor John Kitzhaber signed legislation on Thursday, June 6 designed to address the regulatory issues related to the interchangeability of biological medicines.
The Biotechnology Industry Organization (BIO) and BioFlorida commend the Florida Senate Committee on Health Policy for passage of Senate Bill 732 out of committee.
In statehouses around the country, lawmakers are beginning to address the complexities of cutting-edge biotech drugs and the regulatory issues related to the interchangeability of biosimilar medicines.